Bullfrog AI Holdings Inc. (BFRG): Price and Financial Metrics
BFRG Price/Volume Stats
| Current price | $2.87 | 52-week high | $8.35 |
| Prev. close | $2.91 | 52-week low | $2.36 |
| Day low | $2.78 | Volume | 26,700 |
| Day high | $2.92 | Avg. volume | 2,116,733 |
| 50-day MA | $3.71 | Dividend yield | N/A |
| 200-day MA | $3.48 | Market Cap | 22.53M |
BFRG Stock Price Chart Interactive Chart >
Latest BFRG News From Around the Web
Below are the latest news stories about BULLFROG AI HOLDINGS INC that investors may wish to consider to help them evaluate BFRG as an investment opportunity.
ASP Isotopes and Bullfrog AI Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TVORLANDO, FL / ACCESSWIRE / October 27, 2023 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and BullFrog AI Holdings, Inc. (NASDAQ:BFRG)(NASDAQ:BFRGW) on The RedChip Small Stocks Big Money® Show, a sponsored program on ... |
BullFrog AI to Present at Benzinga All Access Event on October 20GAITHERSBURG, Md., Oct. 18, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that Vin Singh, Founder and CEO of BullFrog AI, will present during Benzinga's All Access investor event on Friday, October 20, 2023, at 11:00 a.m. ET. Webcast: https://www.yo |
BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP™ PlatformDiscoveries generated by analyzing The Cancer Genome Atlas using proprietary bfLEAP™ platform Target validation will be conducted through partnership with J. Craig Venter Institute (JCVI), a world-leading institution in genomics research and innovation GAITHERSBURG, Md., Oct. 05, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable |
BullFrog AI Announces Positive Data from Preclinical Study Evaluating Novel Prodrug of Mebendazole for Treatment of GlioblastomaBullFrog AI’s Patented Drug BF-223 Demonstrates Anti-Cancer Activity Against Glioblastoma in Established Animal ModelGAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced positive data in a preclinical study investigating the an |
BullFrog AI Founder and CEO Vin Singh to Present Company Overview at BioFuture 2023GAITHERSBURG, Md., Sept. 25, 2023 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that its founder and CEO Vin Singh will give a presentation at BioFuture 2023 (Oct. 4-6, 2023) on the Company’s recent partnerships, revenue and growth strategy, and portfoli |
BFRG Price Returns
| 1-mo | -17.77% |
| 3-mo | -59.23% |
| 6-mo | 2.14% |
| 1-year | -45.33% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -11.96% |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...